CHEST GAIN NSCLC
Regional non-small cell lung cancer summits
Engaging an Interdisciplinary Team for NSCLC Diagnosis, Personalized Assessment, and Treatment (GAIN) is an educational curriculum designed for health-care providers to improve their knowledge, skills, and competence in the assessment and management of non-small cell lung cancer (NSCLC).
GAIN Live Summits feature experiential learning; theory-based instructional design with pre-course learning activities; flipped classroom; and interactive, participatory group, and team-based workshop sessions for pulmonology, thoracic surgery, pathology, and oncology clinicians.
Please check back for more registration information.
Washington DC | November 12, 2016
Tampa, FL | January 14, 2017
Atlanta, GA | February 11, 2017
San Francisco, CA | March 11, 2017
St. Louis, MO | April 22, 2017 | REGISTER
Houston, TX | April 29, 2017 | REGISTER
Pittsburgh, PA | May 13, 2017 | REGISTER
Until recently, therapy in advanced NSCLC has been primarily cytotoxic chemotherapy. Now, new information about the molecular origins of cancer, which has been incorporated into the overall approach of targeted therapy, has led to a very complex therapeutic landscape. Also, obtaining adequate tissue samples and performing appropriate testing and analysis of various molecular markers require engagement of an interdisciplinary medical team leading to the identification of optimal therapeutic options, including monoclonal antibodies (MAbs), tyrosine kinase inhibitors (TKIs), and traditional cytotoxic chemotherapy.
Content will address management of locally advanced and metastatic lung cancer by using multidisciplinary and multimodality approaches. These include conventional chemotherapy and biomarker-driven therapy, including immune checkpoint inhibitors that target to unleash or enhance pre-existing anticancer immune responses. Examples of these immunotherapies target PD-1 antibodies, PD-L1 antibodies, and CTLA-4 antibodies. Genotype-driven therapy will be addressed by discussing agents that target genetic abnormalities, including but not limited to: EGFR, KRAS, and BRAF mutations and ALK and ROS1 translocations.
This initiative will engage the following healthcare professional audiences who focus on NSCLC diagnosis and patient care:
- Thoracic Surgeons
- Medical Oncologists
- Relevant Physician Assistants and Nurse Practitioners
- Nurse Navigators and Case Managers
- Improve overall knowledge and competence in relation to tumor biomarkers associated with NSCLC and their relevance for personalized care and targeted therapies.
- Address identified barriers associated with obtaining adequate tissue samples to support the diagnosis and eventual management of NSCLC.
- Improve knowledge, competence, and skills associated with bio-specimen collection and the ability to utilize emerging assays to assess for molecular targets associated with NSCLC.
- Explicate the role of biomarkers, companion diagnostic tests, and immunotherapy.
- Improve ineffective communication pathways and systems-driven “silos” that may impede personalized care for patients with NSCLC.
- Enhance interdisciplinary collaboration with identification of optimal use of medical and surgical therapies for NSCLC.
- Improve clinician knowledge of recent clinical data on current and emerging therapies for NSCLC, including tumor biomarkers, targeted therapy, and immuno-oncology.
- Address barriers to treatment, such as patient comorbidities and therapy side effects.
Eric Edell, MD, FCCP - Chair
Professor of Medicine
Mayo Clinic College of Medicine
Mayo Clinic Rochester
Septimiu Murgu, MD, FCCP - Chair
Associate Professor of Medicine
Co-Director of Bronchoscopy
Program Director, Interventional Pulmonology Fellowship
The University of Chicago Medicine
David Ettinger, MD, FCCP
Alex Grass Professor of Oncology
The Sidney Kimmel Comprehensive Cancer
Center at Johns Hopkins
Rudy P. Lackner, MD, FCCP
Professor of Surgery
Chief, Thoracic Surgery
Director, Residency Program in Cardiothoracic Surgery
University of Nebraska Medical Center
Mari Mino-Kenudson, MD
Pulmonary Pathology Service, Massachusetts General Hospital
Associate Professor of Pathology, Harvard Medical School
This activity is presented through an educational collaboration by the American College of CHEST Physicians (CHEST), the American Society of Clinical Pathology, the National Comprehensive Cancer Network® (NCCN®), and The France Foundation.
This activity is supported by educational grants from Merck and AstaZeneca.